Table 1.
Total of patients | 79 |
Sex (M/F) | 51/28 |
Median age (range) | 44.6 (10–70) |
Diagnosis | 36 AML, 5 NHL, 1 RAEB-2, 8 CLL, 3 MF, 1 PL, 4 MM, 1 LL, 1 HD, 18 ALL,1 AA |
Conditioning (Abl/RIC) | 37/42 |
GvHD prophylaxis | 22/79 ATG (27.8%) 5/79 (6.3%)Campath-1H |
Donor (sib/MUD) | 29/50 |
Stem cell source | CB 8/79 (10.1%), PB 67 /79 (84.8%), BM 4/79 (5.1%) |
GvHD (acute vs chronic) | 27 vs 24 |
AML: acute myeloid leukemia; NHL: non-Hodgkin’s lymphoma; CLL: chronic lymphocitic leukemia; MF: myelofibrosis; PL: plasmacell leukemia; LL: lymphoblastic lymphoma; HL: Hodgkin’s disease; ALL: acute lymphoblastic leukemia; MM: multiple myeloma; AA: aplastic anaemia; RAEB: refractory anemia with excess blasts Abl: ablative; RIC: reduced intensity conditioning.; MUD: matched unrelated donor; CB: cord blood, PB: peripheral blood; BM. bone marrow